{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T13:45:42Z","timestamp":1791380742287,"version":"4.3.3"},"reference-count":20,"publisher":"MedWorks Media","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Psychopharmacol Bull"],"abstract":"<jats:p>Background\nImmunologic measures have been studied as predictors of who will respond to standard antidepressants. Two previous, small studies of pretreatment leukocyte mRNA expression levels of the cytokines macrophage migration inhibitory factor (MIF) and interleukin 1-beta (IL1-\u03b2) identified antidepressant treatment responders.\nMethods\nWe tested these findings in 1,299 patients from the PRIME Care study, a multi-center pharmacogenetic depression treatment trial. Patients underwent 5 depression-symptom assessments over 24 weeks. mRNA was extracted from peripheral blood, purified, and assayed with TaqMan gene expression assays and a known copy number calibrator to yield relative quantification and copy numbers for each sample. In generalized estimating equations models, we regressed the repeated depression measures and a binary treatment response measure on the baseline MIF and IL-1\u03b2 measures and relevant covariates.\nResults\nParticipants\u2019 depression scores decreased monotonically during treatment, with the treatment response percentage increasing concomitantly. We found no significant associations of the cytokine concentrations with either the change in depression scores or the likelihood of a treatment response. A secondary analysis limited to a subsample of 126 participants selected to remove the potential for confounding also showed no significant associations.\nLimitations\nDespite efforts to control for sample and assay method differences, these could have contributed to the lack of replication of prior research.\nConclusions\nWe did not replicate prior findings that pre-treatment expression levels for two cytokines predicted antidepressant treatment response. This raises questions about the clinical utility of using these biomarkers in treating depression.<\/jats:p>","DOI":"10.64719\/pb.4509","type":"journal-article","created":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T11:39:16Z","timestamp":1761046756000},"page":"8-25","source":"Crossref","is-referenced-by-count":0,"title":["Macrophage Migration Inhibitory Factor and Interleukin 1-\u03b2 mRNA Levels as Predictors of Antidepressant Treatment Response in Major Depression"],"prefix":"10.64719","volume":"55","author":[{"given":"Henry R","family":"Kranzler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annjanette","family":"Stone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven A","family":"Schichman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L Michelle","family":"Griffin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah","family":"Roggenkamp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael E","family":"Thase","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin G","family":"Lynch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David W","family":"Oslin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"54175","published-online":{"date-parts":[[2025,8,12]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","unstructured":"Hasin DS, Sarvet AL, Meyers JL, Saha TD, Ruan WJ, Stohl M, Grant BF. Epidemiology of adult DSM-5 major depressive disorder and its specifiers in the United States. JAMA Psychiatry. 2018;75:336\u2013346. doi: 10.1001\/jamapsychiatry.2017.4602.","DOI":"10.1001\/jamapsychiatry.2017.4602"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"Gadermann AM, Engel CC, Naifeh JA, Nock MK, Petukhova M, Santiago PN, Wu B, Zaslavsky AM, Kessler RC. Prevalence of DSM-IV major depression among U.S. military personnel: Meta-analysis and simulation. Mil Med. 2012;177:47\u201359. doi: 10.7205\/MILMED-D-12-00103.","DOI":"10.7205\/MILMED-D-12-00103"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"Fagiolini A, Goracci A. The effects of undertreated chronic medical illnesses in patients with severe mental disorders. J Clin Psychiatry. 2009;70:22\u201329. doi: 10.4088\/JCP.7075su1c.04.","DOI":"10.4088\/JCP.7075su1c.04"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"Moussavi S, Chatterji S, Verdes E, Tandon A, Patel V, Ustun B. Depression, chronic diseases, and decrements in health: Results from the World Health Surveys. The Lancet. 2007;370:851\u2013858. doi: 10.1016\/S0140-6736(07)61415-9.","DOI":"10.1016\/S0140-6736(07)61415-9"},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"Hoge CW, Auchterlonie JL, Milliken CS. Mental health problems, use of mental health services, and attrition from military service after returning from deployment to Iraq or Afghanistan. JAMA. 2006;295:1023\u20131032. doi: 10.1001\/jama.295.9.1023.","DOI":"10.1001\/jama.295.9.1023"},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"Kessler RC, Heeringa SG, Stein MB, Colpe LJ, Fullerton CS, Hwang I, Naifeh JA, Nock MK, Petukhova M, Sampson NA, Schoenbaum M, Zaslavsky AM, Ursano RJ. Thirty-day prevalence of DSM-IV mental disorders among nondeployed soldiers in the US army. JAMA Psychiatry. 2014;71:504\u2013513. doi: 10.1001\/jamapsychiatry.2014.28.","DOI":"10.1001\/jamapsychiatry.2014.28"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"Vaughan CA, Schell TL, Tanielian T, Jaycox LH, Marshall GN. Prevalence of mental health problems among Iraq and Afghanistan veterans who have and have not received VA services. Psychiatr Serv. 2014;65:833\u2013835.","DOI":"10.1176\/appi.ps.201300111"},{"key":"ref8","unstructured":"VA\/DoD Clinical Practice Guideline. Washington, DC: U.S. Government Printing Office; 2022. The management of major depressive disorder."},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"Rush AJ, Trivedi MH, Wisniewski SR, Nierenberg AA, Stewart JW, Warden D, Niederehe G, Thase ME, Lavori PW, Lebowitz BD, McGrath PJ, Rosenbaum JF, Sackeim HA, Kupfer DJ, Luther J, Fava M. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: A STAR*D report. Am J Psychiatry. 2006;163:1905\u20131917. doi: 10.1176\/ajp.2006.163.11.1905.","DOI":"10.1176\/ajp.2006.163.11.1905"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"Ruiz NAL, del \u00c1ngel DS, Brizuela NO, Peraza AV, Olgu\u00edn HJ, Soto MP, Guzm\u00e1n DC. Inflammatory process and immune system in major depressive disorder. Int J Neuropsychopharmacol. 2022;25:46\u201353. doi: 10.1093\/ijnp\/pyab072.","DOI":"10.1093\/ijnp\/pyab072"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"Carvalho LA, Torre JP, Papadopoulos AS, Poon L, Juruena MF, Markopoulou K, Cleare AJ, Pariante CM. Lack of clinical therapeutic benefit of antidepressants is associated overall activation of the inflammatory system. J Affect Disord. 2013;148:136\u2013140. doi: 10.1016\/j.jad.2012.10.036.","DOI":"10.1016\/j.jad.2012.10.036"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"Lanquillon S, Krieg JC, Bening-Abu-Shach U, Vedder H. Cytokine production and treatment response in major depressive disorder. Neuropsychopharmacology. 2000;22:370\u2013379. doi: 10.1016\/S0893-133X(99)00134-7.","DOI":"10.1016\/S0893-133X(99)00134-7"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"Cattaneo A, Gennarelli M, Uher R, Breen G, Farmer A, Aitchison KJ, Craig IW, Anacker C, Zunsztain PA, McGuffin P, Pariante CM. Candidate genes expression profile associated with antidepressants response in the GENDEP study: Differentiating between baseline \u2018predictors\u2019 and longitudinal \u2018targets.\u2019. Neuropsychopharmacology. 2013;38:377\u2013385. doi: 10.1038\/npp.2012.191.","DOI":"10.1038\/npp.2012.191"},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"Powell TR, Schalkwyk LC, Heffernan AL, Breen G, Lawrence T, Price T, Farmer AE, Aitchison KJ, Craig IW, Danese A, Lewis C, McGuffin P, Uher R, Tansey KE, D\u2019Souza UM. Tumor necrosis factor and its targets in the inflammatory cytokine pathway are identified as putative transcriptomic biomarkers for escitalopram response. Eur Neuropsychopharmacol. 2013;23:1105\u20131114. doi: 10.1016\/j.euroneuro.2012.09.009.","DOI":"10.1016\/j.euroneuro.2012.09.009"},{"key":"ref15","doi-asserted-by":"publisher","unstructured":"Cattaneo A, Ferrari C, Uher R, Bocchio-Chiavetto L, Riva MA, Pariante CM. Absolute measurements of macrophage migration inhibitory factor and interleukin-1-\u03b2 mRNA levels accurately predict treatment response in depressed patients. International Journal of Neuropsychopharmacology. 2016;19:pyw045. doi: 10.1093\/ijnp\/pyw045.","DOI":"10.1093\/ijnp\/pyw045"},{"key":"ref16","doi-asserted-by":"publisher","unstructured":"Uher R, Tansey KE, Dew T, Maier W, Mors O, Hauser J, Dernovsek MZ, Henigsberg N, Souery D, Farmer A, McGuffin P. An inflammatory biomarker as a differential predictor of outcome of depression treatment with escitalopram and nortriptyline. Am J Psychiatry. 2014;171:1278\u20131286. doi: 10.1176\/appi.ajp.2014.14010094.","DOI":"10.1176\/appi.ajp.2014.14010094"},{"key":"ref17","doi-asserted-by":"publisher","unstructured":"Oslin DW, Lynch KG, Shih M-C, Ingram EP, Wray LO, Chapman SR, Kranzler HR, Gelernter J, Pyne JM, Stone A, DuVall SL, Lehmann LS, Thase ME, Aslam M, Batki SL, Bjork JM, Blow FC, Brenner LA, Chen P, Desai S, Dieperink EW, Fears SC, Fuller MA, Goodman CS, Graham DP, Haas GL, Hamner MB, Helstrom AW, Hurley RA, Icardi MS, Jurjus GJ, Kilbourne AM, Kreyenbuhl J, Lache DJ, Lieske SP, Lynch JA, Meyer LJ, Montalvo C, Muralidhar S, Ostacher MJ, Paschall GY, Pfeiffer PN, Prieto S, Przygodzki RM, Ranganathan M, Rodriguez-Suarez MM, Roggenkamp H, Schichman SA, Schneeweis JS, Simonetti JA, Steinhauer SR, Suppes T, Umbert MA, Vassy JL, Voora D, Wiechers IR, Wood AE. Effect of pharmacogenomic testing for drug-gene interactions on medication selection and remission of symptoms in major depressive disorder: The PRIME Care randomized clinical trial. JAMA. 2022;328:151\u2013161. doi: 10.1001\/jama.2022.9805.","DOI":"10.1001\/jama.2022.9805"},{"key":"ref18","doi-asserted-by":"publisher","unstructured":"Rothschild AJ, Parikh SV, Hain D, Law R, Thase ME, Dunlop BW, DeBattista C, Conway CR, Forester BP, Shelton RC, Macaluso M, Brown K, Lewis D, Gutin A, Jablonski MR, Greden JF. Clinical validation of combinatorial pharmacogenomic testing and single-gene guidelines in predicting psychotropic medication blood levels and clinical outcomes in patients with depression. Psychiatry Res. 2021;296 doi: 10.1016\/j.psychres.2020.113649.","DOI":"10.1016\/j.psychres.2020.113649"},{"key":"ref19","doi-asserted-by":"publisher","unstructured":"Kroenke K, Spitzer RL, Williams JBW. The PHQ-9. J Gen Intern Med. 2001;16:606\u2013613. doi: 10.1046\/j.1525-1497.2001.016009606.x.","DOI":"10.1046\/j.1525-1497.2001.016009606.x"},{"key":"ref20","doi-asserted-by":"publisher","unstructured":"Mahboudi H, Heidari NM, Rashidabadi ZI, Anbarestani AH, Karimi S, Darestani KD. Prospect and competence of quantitative methods via real-time PCR in a comparative manner: An experimental review of current methods. Open Bioinforma J. 2018;11:1\u201311. doi: 10.2174\/1875036201811010001.","DOI":"10.2174\/1875036201811010001"}],"container-title":["Psychopharmacology Bulletin"],"original-title":[],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T19:33:03Z","timestamp":1791315183000},"score":1,"resource":{"primary":{"URL":"https:\/\/medworksmedia.com\/pb-article\/macrophage-migration-inhibitory-factor-and-interleukin-1-%ce%b2-mrna-levels-as-predictors-of-antidepressant-treatment-response-in-major-depression\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,12]]},"references-count":20,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,8,12]]}},"URL":"https:\/\/doi.org\/10.64719\/pb.4509","relation":{},"ISSN":["2472-2448"],"issn-type":[{"value":"2472-2448","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,12]]}}}